Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06669416 · ClinicalTrials.gov registry record · NA

Taste Alterations Study

A NA study of Taste, Altered and Chemotherapy Side Effects, sponsored by Wake Forest University Health Sciences.

Recruiting
Registry status
NA
Development phase
400
Enrollment target
1
Study location

NCT06669416: Recruiting NA study of Taste, Altered and Chemotherapy Side Effects, sponsored by Wake Forest University Health Sciences.

NCT06669416 is a NA study of Taste, Altered and Chemotherapy Side Effects that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 400 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06669416, a NA study of Taste, Altered and Chemotherapy Side Effects, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.

RECRUITING
Registry status
NA
Development phase
400 participants
Enrollment target
1
Study location

Study Summary

The main questions it aims to answer are: 1. Does completing a standard assessment increase the detection of chemotherapy induced taste changes compared with usual care (no assessment)? What TA are experienced? Are there any patterns in TA symptom occurrence based on age, sex, race/ethnicity, cancer type, chemotherapy agent, etc. 2. Do patients take action to deal with the TA? What strategies are used? Do patients in the intervention group use the assessments to select interventions? 3. Do the interventions lessen TA symptoms and maintain food intake? Is the treatment (in-depth assessment and education) more effective in lessening the intensity of TA than usual care? Which level of assessment is needed to support symptom management to reduce symptom severity? Participants will: Complete baseline assessment before starting their initial chemotherapy infusion (all patients) Participate in baseline patient education based on assigned intervention (usual care vs. treatment) Engage in TA management between chemotherapy infusion clinic visits based on education Visit the clinic for chemotherapy infusions as scheduled; Complete TA assessments and reporting based on intervention; Work with nurse coaches to answer questions and help with the intervention. Complete study data collection on the 4th chemotherapy cycle (but continue intervention) Complete final data collection at 6 months

Primary Outcome

A single item question with ordinal rating will be used to confirm taste alterations and evaluate severity of TA (control) The CiTAS tool (18 item ordinal rating tool) will be used to confirm taste alterations and evaluate severity of TA (treatment)

Interventions

  • BEHAVIORAL Taste Alteration Self-Assessment
  • BEHAVIORAL Taste Alternation Self-Management

Study Locations (1)

Illinois

  • Advocate Illinois Masonic Medical Center - Chicago

Trial Details

FieldValue
Enrollment Target 400 participants
Start Date 2024-12-01
Est. Completion 2026-05
Phase NA
Wake Forest University Health Sciences

1,140 total trials

What NCT06669416 shows while recruiting

NCT06669416 is an interventional study that assigns participants to a tested intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (72% lower).

The record links to 2 conditions, with Taste, Altered appearing as the primary indexed condition, and to 2 interventions - of which Taste Alteration Self-Assessment is the first listed.

NCT06669416 reports a single indexed study location in Illinois.

Frequently Asked Questions

What is clinical trial NCT06669416 about?

NCT06669416 is a clinical study titled "Taste Alterations Study". The main questions it aims to answer are: 1. Does completing a standard assessment increase the detection of chemotherapy induced taste changes compared with usual care (no assessment)? What TA are experienced? Are there any patterns in TA symptom occurrence based on age, sex, race/ethnicity, cance...

What is the current status of trial NCT06669416?

This trial is currently recruiting. It is a NA study. The enrollment target is 400 participants. The study started on 2024-12-01. Estimated completion is 2026-05.

What conditions does trial NCT06669416 study?

This clinical trial studies the following conditions: Taste, Altered, Chemotherapy Side Effects.

What interventions are being tested in trial NCT06669416?

The interventions under investigation include: Taste Alteration Self-Assessment (BEHAVIORAL), Taste Alternation Self-Management (BEHAVIORAL).

Who is sponsoring clinical trial NCT06669416?

This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06669416 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Taste, Altered

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06669416's enrollment target sits among peer trials

400 246th of 2000 higher than 1,734 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01665326 · 400 participants

    Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease

  • NCT02108054 · 400 participants · NA

    Behavioral and Functional Task Development, Implementation, and Testing

  • NCT02216500 · 400 participants · NA

    Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy

  • NCT02250352 · 400 participants

    Core Biopsies for Establishing a Breast Tumor Tissue Repository

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06669416, the US trial registry maintained by the National Library of Medicine. NCT06669416 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.